Notice Concerning Status of Acquisition of Treasury Shares
Filed with TSE · · 1 page · English
Kissei Pharmaceutical Co., Ltd. on 6ix
Story so far
- Notice Concerning the Results of the Acquisition of Treasury Shares, Through Off Auction Treasury Share Repurchase Trading System (ToSTNeT 3), the Completion of Acquisition of Treasury shares and the Cancellation of Treasury Shares
- Notice on the Acquisition of Treasury Shares, the Acquisition of Treasury Shares Through Off Auction Own Share Repurchase Trading System (ToSTNeT 3) and the Cancellation of Treasury Shares
- Notice Concerning Status of Acquisition and Completion of the Company's Own Shares
Earlier from Kissei Pharmaceutical
- Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
- Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
- Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
- The Opening of a new Office for Open Innovation in the Boston Area
- Kissei Pharmaceutical Initiates Phase III Clinical Trial for GnRH Antagonist "Linzagolix" Indicated for Endometriosis
Later from Kissei Pharmaceutical
- Notice Concerning Disposal of Treasury Shares as Restricted Stock for Members of the Board and Corporate Officers
- Announcement for the Opnion by European Authorities on TAVNEOS
- Consolidated Financial Results for the Three Months Ended June 30, 2026 [Japanese GAAP]
- Notice of Completion of Payment for Treasury Shares Disposal as Restricted Stock for Employee Shareholding Association and Partial
- Announcement for the Results Report by the Council of Pharmaceutical Affairs (Mdical Product Second Section) on TAVNEOS
Follow Kissei Pharmaceutical into a list and get an email when it puts out news.
Follow Kissei Pharmaceutical